Understanding the Role of Radio-Sensitizing Nanoparticles in Enhancing Pathologic Response in Soft Tissue Sarcomas

Author:

Stergioula Anastasia1ORCID,Pantelis Evaggelos2ORCID,Kontogeorgakos Vasileios3,Lazaris Andreas C.1ORCID,Agrogiannis Georgios1

Affiliation:

1. First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece

2. Medical Physics Laboratory, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece

3. First Department of Orthopaedic Surgery, Attikon University General Hospital, 12462 Athens, Greece

Abstract

High-atomic-number (Z) nanoparticles produce a cascade of low-energy secondary electrons and characteristic X-rays when ionized by X-ray irradiation. These secondary particles deposit their energy in the vicinity of the nanoparticles and, provided that the latter are selectively accumulated within tumor cells, this results in increased DNA damage and tumor cell deaths. This study reviews the utilization of high-Z nanoparticles in the treatment of soft tissue sarcomas (STS). Both in vitro and in vivo experiments demonstrated that the dose is enhanced by approximately 1.2 when polyethelyne glycol (PEG)-modified gold nanoparticles, and from 1.4 to 1.8 when hafnium oxide nanoparticles (NBTXR3, Nanobiotix SA, France) are introduced into tumor cells and activated by X-ray beams. In a phase 2/3 clinical trial investigating the therapeutic benefit of using nanoparticles in preoperative external beam radiotherapy for locally advanced STS, the proportion of patients with a pathological complete response in their resected tumor was doubled when NBTXR3 nanoparticles were used. Additionally, a higher percentage of patients with complete tumor resection was observed in the NBTXR3 plus radiotherapy group. Similar toxicity profiles were found for both the NBTXR3 plus radiotherapy and the radiotherapy alone patient groups. The incorporation of radio-sensitizing nanoparticles in the preoperative radiotherapy of STS could enhance treatment outcomes.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference58 articles.

1. Soft-tissue Sarcoma in Adults: An Update on the Current State of Histiotype-specific Management in an Era of Personalized Medicine;Gamboa;CA Cancer J. Clin.,2020

2. Soft-Tissue Sarcomas in Adults;Clark;N. Engl. J. Med.,2005

3. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (2023, November 11). Soft Tissue Sarcoma (Version 2). Available online: https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf.

4. UK Guidelines for the Management of Soft Tissue Sarcomas;Dangoor;Clin. Sarcoma Res.,2016

5. Soft Tissue and Visceral Sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up;Gronchi;Ann. Oncol.,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3